ARTICLE | Company News
MuriGen, CSL deal
November 3, 2008 8:00 AM UTC
The partners amended a 2006 deal, giving CSL full responsibility for developing and commercializing antibodies that inhibit G-CSF or its receptor to treat arthritis and inflammatory diseases. In retur...